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Thinly myelinated group III and unmyelinated group IV skeletal muscle afferents are 24 
important tools in the armoury of homeostasis. Activated by mechanical and/or 25 
metabolic stimuli, they are part responsible for reflex increases in cardiac and 26 
peripheral sympathetic output during exercise. Their activity helps maintain a 27 
balance between vasoconstriction and vasodilatation, respectively preventing 28 
unsuitable increases in local vascular resistance and generalised hypotension. 29 
However, aberrant skeletal muscle afferent activation has been implicated in the 30 
genesis of exercise intolerance in heart failure (HF) patients. Therefore, in a recent 31 
issue of Journal of Physiology, Smith et al. (2020) scrutinised the contribution of 32 
feedback afferents on cardiac and peripheral hemodynamics to determine which 33 
mechanisms are responsible for reduced exercise capacity in HF.  34 
Eleven (61±9 years) reduced ejection fraction HF patients performed incremental 35 
cycling exercise until volitional fatigue with and without 50 µg lumber intrathecal 36 
(subarachnoid) fentanyl (μ‐opioid receptor agonist) injection; participants were asked 37 
to remain seated to prevent cephalic migration of fentanyl. Resting cardiovascular, 38 
ventilatory, and blood gas parameters were not affected by fentanyl suggesting 39 
minimal contribution of muscle afferents to resting cardiorespiratory parameters in 40 
HF. Crucially, fentanyl improved peak workload, peak oxygen (O2) uptake (VO2), and 41 
minute ventilation. Improved exercise capacity was accompanied by lower venous 42 
(femoral) O2 content, O2 saturation, and pH alongside increased venous CO2 content 43 
at peak workload, suggesting muscle afferent overactivity is an important contributor 44 
to VO2 and exercise capacity limitations in HF patients. Systolic, diastolic, and mean 45 
blood pressure (BP) at peak workload were lower. Importantly, afferent blockade 46 
with fentanyl decreased resistance to stroke volume in HF patients subsequently 47 
increasing stroke volume and cardiac output. When matched for peak placebo 48 
workload, intrathecal fentanyl was again shown to improve stroke volume and lower 49 
heart rate in HF patients. Systolic, diastolic, and mean BP were all lower while leg 50 
vascular conductance was improved. Collectively, these novel findings indicate 51 
exaggerated locomotor afferent activity constrains VO2 and exercise capacity / 52 
tolerance by restricting central / cardiac hemodynamic contributions in HF patients.  53 
Amann et al. (2014) used intrathecal fentanyl with a one-leg knee extensor model to 54 
show afferent blockade reverses the inappropriate increases in noradrenaline spill-55 
over and vascular resistance to improve tissue perfusion in HF patients. Moreover, 56 
this increased leg VO2 and lowered the ratings of perceived exertion. Exercise 57 
induced increases in cardiac output and stroke volume were found to be attenuated 58 
with fentanyl, suggesting positive / necessary inotropic contributions of muscle 59 
afferents to perfusion dynamics in HF. Using two-leg cycling until fatigue, Smith et al. 60 
(2020) also show aberrant afferent activity contributes to exercise intolerance in HF. 61 
However importantly, their novel findings show that exercise intolerance in HF is a 62 
direct consequence of a decrease in stroke volume, which itself is a function of 63 
inappropriately exaggerated vascular resistance. This recent work, in agreement with 64 
numerous previous findings, also suggests pressor responses in HF are primarily 65 
maintained by a vasoconstrictor sympathetic influence that can negatively impact 66 
cardiac inotropic activity. The conflicting inotropic / cardiac output contributions of 67 
muscle afferents between Amann et al. (2014) and Smith et al. (2020) may reflect 68 
discrepant exercise models, which may be differentially affecting peripheral 69 
sympathetic activity, cardiac autonomic function, baroreceptor function, renal and/or 70 
splanchnic redistribution of perfusion. Indeed, when matched for workload with and 71 
without fentanyl, both studies show divergent exercise induced inotropic and 72 
chronotropic effects. Moreover, it is also possible that the single-leg knee extensor 73 
exercise simply failed to significantly increase peripheral resistance to an extent that 74 
could negatively impact cardiac afterload and stroke volume. Nonetheless, in accord, 75 
Amann et al. (2014) and Smith et al. (2020), both show that afferent blockade in HF 76 
patients with fentanyl increases vascular conductance of the exercising muscles 77 
which enhances their VO2 and general exercise capacity / tolerance. Therefore, 78 
inadequate muscle perfusion and O2 transport, driven by amplified peripheral 79 
resistance and/or cardiac insufficiency, may be the “principal” determinant of 80 
exercise intolerance in HF. 81 
As reviewed by Vianna and Fisher (2019), muscle atrophy and shift towards 82 
glycolytic fibres are important aspects of the “muscle hypothesis of HF”. Besides the 83 
fore mentioned discussion on Smith et al. (2020), their results also suggest that the 84 
direct role of muscle atrophy and a fibre-type switch may be of less importance to 85 
exercise intolerance in HF compared to centrally and peripherally mediated 86 
reductions in nutritive muscle perfusion. Separately, mechanical cardiac dysfunction 87 
may pre-sensitise feedback afferents due to muscle under-perfusion, hypoxia and/or 88 
ischemia. Normally, exercise leads to intra- and extravascular release of vasodilator 89 
metabolites to cause functional hyperaemia and sympatholysis. However, some of 90 
the vasoactive metabolites also stimulate and sensitize group III and IV muscle 91 
afferents. It is possible that the dysfunctional activity of vasoactive metabolites 92 
and/or their receptors alongside pre-sensitised muscle afferents is partly to blame for 93 
inadequate muscle perfusion. Additionally, patient inactivity may also be adding to 94 
the muscle perfusion and sympatholysis limitations. In agreement, improvements in 95 
VO2 and exercise tolerance have been observed with cardiac resynchronisation 96 
therapy, which are further enhanced by structured exercise therapy (Conraads et al., 97 
2007).  98 
Design considerations 99 
Fentanyl is a selective µ-opioid receptor agonist and fails to influence δ-opioid 100 
receptors. Further, at the administered dosage fentanyl probably only partially 101 
disrupts µ-opioid signalling. Therefore, the results described reflect partial / 102 
incomplete afferent blockade, enhancing the importance of recognising aberrant 103 
restrictive afferent influences on nutritive muscle / tissue perfusion during exercise in 104 
HF patients. Observations of Smith et al. (2020) reflect combined attenuation of 105 
group III and group IV afferent activity; magnitude of their individual contributions 106 
remains unknown and is an area of active exploration / discussion. Most HF patients 107 
have comorbidities which are independently associated with exercise intolerance. 108 
Acknowledging the group homogeneity, Smith et al. (2020) do not report any specific 109 
comorbidities in their subjects. Some of their participants are on anti-hypertensive 110 
medications and the reported body-mass-index is also somewhat higher than 111 
normal. Therefore, possible additional influence of hypertension, diabetes, and/or 112 
metabolic diseases cannot be excluded from their observations. Lastly, group III and 113 
group IV afferents depress motor cortical excitability to restrict motor neurons and 114 
locomotor output, at least in young healthy individuals performing cycling time trials 115 
(Amann et al., 2020). Paucity of clear information exists regarding the role of central 116 
neural fatigue in HF. From the few studies that have attempted to investigate, most 117 
have failed to register it as a major contributor whilst one observed significant 118 
correlation between muscle fatigability and attenuated surface electromyograph 119 
activity. Therefore, exercise intolerance in HF may reflect some motoneuronal output 120 
inhibition / central fatigue, which is at least part-reversed with intrathecal fentanyl. 121 
This hypothesis and the central neural mechanisms of fatigability in HF warrant 122 
further direct exploration. In conclusion, Smith et al. (2020) show exercise 123 
intolerance in HF is a function of stroke volume constraints due to aberrant 124 
vasoconstrictor activity of muscle afferents. Their novel work offers interesting 125 
insights and provides direction for many future follow‐up studies.  126 
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